Detalhe da pesquisa
1.
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Gynecol Oncol
; 178: 44-53, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37748270
2.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722153
3.
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Gynecol Oncol
; 162(2): 482-495, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090705
4.
Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Gynecol Oncol
; 156(3): 662-668, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31918995
5.
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
Gynecol Oncol
; 158(1): 16-24, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386911
6.
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Gynecol Oncol
; 156(3): 561-567, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31982178
7.
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Gynecol Oncol
; 154(1): 199-206, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30987772
8.
Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
Int J Gynecol Cancer
; 28(2): 302-307, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360690
9.
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Gynecol Oncol
; 143(3): 484-489, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27726923
10.
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 143(3): 511-515, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692669
11.
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Gynecol Oncol
; 139(1): 23-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260910
12.
Patient preferences in advanced or recurrent ovarian cancer.
Cancer
; 120(23): 3651-9, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25091693
13.
Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.
Gynecol Oncol
; 133(2): 211-5, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24582867
14.
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
J Clin Oncol
; 42(2): 170-179, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37906726
15.
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
Cancer
; 119(20): 3653-61, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23921967
16.
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.
Gynecol Oncol
; 130(1): 156-61, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23587882
17.
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
Gynecol Oncol
; 130(1): 64-8, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591400
18.
Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series.
Gynecol Oncol Rep
; 50: 101297, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38033361
19.
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.
Lancet Gastroenterol Hepatol
; 8(10): 908-918, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541263
20.
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Cancer
; 118(13): 3283-93, 2012 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22072307